Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Antimycobacterial Susceptibility Testing Group

doi:10.1183/13993003.00166-2022

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Antimycobacterial Susceptibility Testing Group

Unidad de Bacteriología y Microbacterias, CIB-UPB

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

19 Citas (Scopus)

Idioma original	Inglés
Número de artículo	2200166
Publicación	European Respiratory Journal
Volumen	59
N.º	4
DOI	https://doi.org/10.1183/13993003.00166-2022
Estado	Publicada - 1 abr. 2022

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1183/13993003.00166-2022

Citar esto

@article{0f5fab63f4d049de9bd2b904d1afd430,

title = "Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment",

author = "{Antimycobacterial Susceptibility Testing Group} and Georghiou, {Sophia B.} and Rodwell, {Timothy C.} and Alexei Korobitsyn and Abbadi, {Said H.} and Kanchan Ajbani and Alffenaar, {Jan Willem} and David Alland and Nataly Alvarez and S{\"o}nke Andres and Elisa Ardizzoni and Alexandra Aubry and Rossella Baldan and Marie Ballif and Ivan Barilar and B{\"o}ttger, {Erik C.} and Soumitesh Chakravorty and Claxton, {Pauline M.} and Cirillo, {Daniela M.} and I{\~n}aki Comas and Chris Coulter and Denkinger, {Claudia M.} and Brigitta Derendinger and Desmond, {Edward P.} and {de Steenwinkel}, {Jurriaan E.M.} and Keertan Dheda and Diacon, {Andreas H.} and Dolinger, {David L.} and Dooley, {Kelly E.} and Matthias Egger and Soudeh Ehsani and Farhat, {Maha R.} and Lanfranco Fattorini and Iris Finci and {Le Ray}, {Laure Fournier} and Victoria Furi{\'o} and Ramona Groenheit and Tawanda Gumbo and Heysell, {Scott K.} and Doris Hillemann and Harald Hoffmann and Hsueh, {Po Ren} and Yi Hu and Hairong Huang and Alamdar Hussain and Farzana Ismail and Kiyohiko Izumi and Tomasz Jagielski and Johnson, {John L.} and Priti Kambli and Jaime Robledo",

note = "Funding Information: Support statement: As current or former employees or consultants for FIND, the work of R.B. Baldan, I. Comas, C.M. Denkinger, D.L. Dolinger, S.B. Georghiou, C.U. K{\"o}ser and T.C. Rodwell on the systematic reviews, including this viewpoint, was supported by Unitaid (grant 2019-32-FIND MDR), BMGF (grant OPP1105925), the German Federal Ministry of Education and Research through KfW, the Dutch Ministry of Foreign Affairs, the Australian Department of Foreign Affairs and Trade, and UK aid from the British people. N. Alvarez and J. Robledo are funded by MinCiencias, Colombia (number 221389666216 CT-783-2018). A. Aubry and N. Veziris work at the Centre National de Reference des Mycobact{\'e}ries, which receives an annual grant from Sant{\'e} Publique France and have received research grants from Janssen for studies on bedaquiline. P. Claxton and I.F. Laurenson are funded through National Services Scotland. I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038). M. Egger is supported by the Swiss National Science Foundation (grant number 320030_153442 and 189498) and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919. M.R. Farhat is supported by NIH NIAID R01AI155765. S.K. Heysell was funded by NIH NIAID grants R01 AI137080 and U01 AI150508. T. Jagielski was supported by a DAINA grant (number 2017/27/L/NZ6/03279) from the National Science Centre, Poland. J.L. Johnson was supported by contracts NO1-AI95383 and NO1-AI-70022 of the US National Institutes of Health. P.M. Keller was supported by Innosuisse 36198.1 IP-LS. C.U. K{\"o}ser is a research associate at Wolfson College and visiting scientist at the Department of Genetics, University of Cambridge. The Federal Government of Germany supported C.U. K{\"o}ser as part of his work for the European Laboratory Initiative, WHO Regional Office for Europe. C.U. K{\"o}ser was further supported by the Royal Society of Tropical Medicine and Hygiene and the National Institute for Health Research Cambridge Biomedical Research Centre and received an observership by the European Society of Clinical Microbiology and Infectious Diseases to the EUCAST Development Laboratory for Bacteria (V{\"a}xj{\"o}, Sweden), hosted by Gunnar Kahlmeter and Erika Matuschek. D. Machado and M. Viveiros are funded in part by Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia, Portugal (PTDC/BIA-MIC/30692/2017, UID/Multi/04413/2020 and DL57/ CEECIND/0256/2017). S. Niemann is supported by the German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation EXC 2167, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG). S.V. Omar has received funding to prepare and provide training for Janssen Pharmaceutica activities. L. Rigouts is supported by the Belgian Directorate General for Development. T.C. Rodwell was additionally funded in part by FIND and NIH NIAD, grants: P30 AI036214 and R21 AI135756. T. Sch{\"o}n is funded by the Swedish Heart and Lung Foundation and the Swedish Research Council. T.R. Sterling has received funding from the US National Institutes of Health and the Centers for Disease Control and Prevention. G. Theron and R. Warren are supported by baseline funding from the South African Medical Research Council. R.J. Wilkinson receives funding from the Wellcome Trust (203135) and from the Francis Crick Institute, which is supported by Cancer Research UK (FC0010218), UKRI (FC0010218) and the Wellcome Trust (FC0010218). The views expressed here are those of the authors and do not necessarily correspond to those of their respective employers.",

year = "2022",

month = apr,

day = "1",

doi = "10.1183/13993003.00166-2022",

language = "Ingl{\'e}s",

volume = "59",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "4",

}

TY - JOUR

T1 - Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents

T2 - implications for diagnosis and treatment

AU - Antimycobacterial Susceptibility Testing Group

AU - Georghiou, Sophia B.

AU - Rodwell, Timothy C.

AU - Korobitsyn, Alexei

AU - Abbadi, Said H.

AU - Ajbani, Kanchan

AU - Alffenaar, Jan Willem

AU - Alland, David

AU - Alvarez, Nataly

AU - Andres, Sönke

AU - Ardizzoni, Elisa

AU - Aubry, Alexandra

AU - Baldan, Rossella

AU - Ballif, Marie

AU - Barilar, Ivan

AU - Böttger, Erik C.

AU - Chakravorty, Soumitesh

AU - Claxton, Pauline M.

AU - Cirillo, Daniela M.

AU - Comas, Iñaki

AU - Coulter, Chris

AU - Denkinger, Claudia M.

AU - Derendinger, Brigitta

AU - Desmond, Edward P.

AU - de Steenwinkel, Jurriaan E.M.

AU - Dheda, Keertan

AU - Diacon, Andreas H.

AU - Dolinger, David L.

AU - Dooley, Kelly E.

AU - Egger, Matthias

AU - Ehsani, Soudeh

AU - Farhat, Maha R.

AU - Fattorini, Lanfranco

AU - Finci, Iris

AU - Le Ray, Laure Fournier

AU - Furió, Victoria

AU - Groenheit, Ramona

AU - Gumbo, Tawanda

AU - Heysell, Scott K.

AU - Hillemann, Doris

AU - Hoffmann, Harald

AU - Hsueh, Po Ren

AU - Hu, Yi

AU - Huang, Hairong

AU - Hussain, Alamdar

AU - Ismail, Farzana

AU - Izumi, Kiyohiko

AU - Jagielski, Tomasz

AU - Johnson, John L.

AU - Kambli, Priti

AU - Robledo, Jaime

N1 - Funding Information: Support statement: As current or former employees or consultants for FIND, the work of R.B. Baldan, I. Comas, C.M. Denkinger, D.L. Dolinger, S.B. Georghiou, C.U. Köser and T.C. Rodwell on the systematic reviews, including this viewpoint, was supported by Unitaid (grant 2019-32-FIND MDR), BMGF (grant OPP1105925), the German Federal Ministry of Education and Research through KfW, the Dutch Ministry of Foreign Affairs, the Australian Department of Foreign Affairs and Trade, and UK aid from the British people. N. Alvarez and J. Robledo are funded by MinCiencias, Colombia (number 221389666216 CT-783-2018). A. Aubry and N. Veziris work at the Centre National de Reference des Mycobactéries, which receives an annual grant from Santé Publique France and have received research grants from Janssen for studies on bedaquiline. P. Claxton and I.F. Laurenson are funded through National Services Scotland. I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038). M. Egger is supported by the Swiss National Science Foundation (grant number 320030_153442 and 189498) and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919. M.R. Farhat is supported by NIH NIAID R01AI155765. S.K. Heysell was funded by NIH NIAID grants R01 AI137080 and U01 AI150508. T. Jagielski was supported by a DAINA grant (number 2017/27/L/NZ6/03279) from the National Science Centre, Poland. J.L. Johnson was supported by contracts NO1-AI95383 and NO1-AI-70022 of the US National Institutes of Health. P.M. Keller was supported by Innosuisse 36198.1 IP-LS. C.U. Köser is a research associate at Wolfson College and visiting scientist at the Department of Genetics, University of Cambridge. The Federal Government of Germany supported C.U. Köser as part of his work for the European Laboratory Initiative, WHO Regional Office for Europe. C.U. Köser was further supported by the Royal Society of Tropical Medicine and Hygiene and the National Institute for Health Research Cambridge Biomedical Research Centre and received an observership by the European Society of Clinical Microbiology and Infectious Diseases to the EUCAST Development Laboratory for Bacteria (Växjö, Sweden), hosted by Gunnar Kahlmeter and Erika Matuschek. D. Machado and M. Viveiros are funded in part by Fundação para a Ciência e a Tecnologia, Portugal (PTDC/BIA-MIC/30692/2017, UID/Multi/04413/2020 and DL57/ CEECIND/0256/2017). S. Niemann is supported by the German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation EXC 2167, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG). S.V. Omar has received funding to prepare and provide training for Janssen Pharmaceutica activities. L. Rigouts is supported by the Belgian Directorate General for Development. T.C. Rodwell was additionally funded in part by FIND and NIH NIAD, grants: P30 AI036214 and R21 AI135756. T. Schön is funded by the Swedish Heart and Lung Foundation and the Swedish Research Council. T.R. Sterling has received funding from the US National Institutes of Health and the Centers for Disease Control and Prevention. G. Theron and R. Warren are supported by baseline funding from the South African Medical Research Council. R.J. Wilkinson receives funding from the Wellcome Trust (203135) and from the Francis Crick Institute, which is supported by Cancer Research UK (FC0010218), UKRI (FC0010218) and the Wellcome Trust (FC0010218). The views expressed here are those of the authors and do not necessarily correspond to those of their respective employers.

PY - 2022/4/1

Y1 - 2022/4/1

UR - http://www.scopus.com/inward/record.url?scp=85129331780&partnerID=8YFLogxK

U2 - 10.1183/13993003.00166-2022

DO - 10.1183/13993003.00166-2022

M3 - Artículo de revisión

C2 - 35422426

AN - SCOPUS:85129331780

SN - 0903-1936

VL - 59

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 4

M1 - 2200166

ER -